EVAg

LCMV expression plasmid used to make a cell line that stably expresses the GPC of LCMV strain WE. [Alternative name: pDP338]

Plasmid for expression of the LCMV L-segment in rodent cells; [also termed pDP065]; depends on cellular rescue by appropriate host cell

Plasmid for expression of the LCMV S-segment with heterologous arenavirus GP - Machupo

Plasmid for expression of the LCMV S-segment with heterologous arenavirus GP - Tacaribe

Plasmid for expression of the LCMV S-segment with heterologous arenavirus GP - Ampari

Plasmid for expression of the LCMV S-segment with heterologous arenavirus GP - Guanarito

Plasmid for expression of the LCMV S-segment with heterologous arenavirus GP - Tamiami

Plasmid for expression of the LCMV S-segment with heterologous arenavirus GP - Junin vaccine strain XJ

Plasmid for expression of the LCMV S-segment with heterologous arenavirus GP - Junin with glycosylation site restored as described in Sommerstein et al. 2015 PLoS Pathos.

Plasmid for expression of the LCMV S-segment with heterologous arenavirus GP - Lassa strain Josiah

Fusion protein of LCMV-GP-1 with the human Fc receptor; soluble recombinant protein

LCMV full length glycoprotein coupled with the human Fc receptor for ELISA application

Reverse genetics-based life cycle modelling system that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and Lloviu virus entry into target cells under BSL1 conditions.

Reverse genetics-based life cycle modelling system that can serve as negative control and is best used together with other trVLP systems that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and entry into target cells under BSL1 conditions.

Target region of a specific Real time assay was amplified and cloned.

Plasmid for in vitro transcription that contains the 5`UTR region of an Aichi virus for 5`UTR-Leader region PCR assays published by Drexler et al, Emerg Infect Dis. 2011

Human Coronavirus 229E plasmid for in vitro transcription.

monoclonal antiserum, IgG and conjugate for ELISA-testing

Reverse genetics-based life cycle modelling system that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and entry into target cells under BSL1 conditions.

Reverse genetics-based life cycle modelling system that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and entry into target cells under BSL1 conditions.

Reverse genetics-based life cycle modelling system that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and entry into target cells under BSL1 conditions.

Reverse genetics-based life cycle modelling system that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and Sudan virus entry into target cells under BSL1 conditions.

Reverse genetics-based life cycle modelling system that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and Sudan virus entry into target cells under BSL1 conditions.

Reverse genetics-based life cycle modelling system (8 plasmids) that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and Reston virus entry into target cells under BSL1 conditions.

Reverse genetics-based life cycle modelling system that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and Reston virus entry into target cells under BSL1 conditions.